Literature DB >> 8119066

Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected].

B Peterson1, S L George.   

Abstract

This paper provides equations for calculating the sample size necessary to test an interaction effect in an 2 x k factorial design when time-to-failure is the outcome of interest. The results are a direct extension of those used by George and Desu and Makuch and Simon who provide sample size requirements for comparing two and k treatment groups, respectively. Duration of a clinical trial concerned with an interaction is calculated using the results of Rubinstein, Gail, and Santner. The results in the present paper can also be used to investigate the impact that an unforeseen interaction has on the power to detect a treatment main effect. This impact can be substantial, even for moderate interactions.

Mesh:

Substances:

Year:  1993        PMID: 8119066     DOI: 10.1016/0197-2456(93)90031-8

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  21 in total

Review 1.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

2.  Statistical and practical considerations for clinical evaluation of predictive biomarkers.

Authors:  Mei-Yin C Polley; Boris Freidlin; Edward L Korn; Barbara A Conley; Jeffrey S Abrams; Lisa M McShane
Journal:  J Natl Cancer Inst       Date:  2013-10-17       Impact factor: 13.506

3.  Use of archived specimens in evaluation of prognostic and predictive biomarkers.

Authors:  Richard M Simon; Soonmyung Paik; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2009-10-08       Impact factor: 13.506

4.  Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.

Authors:  Dario Pasalic; Deborah A Kuban; Pamela K Allen; Chad Tang; Shane M Mesko; Stephen R Grant; Alexander A Augustyn; Steven J Frank; Seungtaek Choi; Karen E Hoffman; Quynh-Nhu Nguyen; Sean E McGuire; Alan Pollack; Mitchell S Anscher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-02       Impact factor: 7.038

5.  The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS).

Authors:  David B Matchar; Alan K Jacobson; Robert G Edson; Philip W Lavori; Jack E Ansell; Michael D Ezekowitz; Frederick Rickles; Lou Fiore; Kathy Boardman; Ciaran Phibbs; Stephan D Fihn; Julia E Vertrees; Rowena Dolor
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

6.  Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Authors:  Stefan Michiels; Richard F Potthoff; Stephen L George
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

Review 7.  Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2017-09-01       Impact factor: 13.506

8.  Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.

Authors:  Joshua I Barzilay; Barry R Davis; Sara L Pressel; Jeffrey A Cutler; Paula T Einhorn; Henry R Black; William C Cushman; Charles E Ford; Karen L Margolis; Jamaluddin Moloo; Suzanne Oparil; Linda B Piller; Debra L Simmons; Mary Ellen Sweeney; Paul K Whelton; Nathan D Wong; Jackson T Wright
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-03-06

9.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa.

Authors:  S A Allen; R Musonda; S Trask; B H Hahn; H Weiss; J Mulenga; F Kasolo; S H Vermund; G M Aldrovandi
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-01       Impact factor: 2.205

10.  Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.

Authors:  Paymaneh D Malihi; Ryon P Graf; Angel Rodriguez; Naveen Ramesh; Jerry Lee; Ramsay Sutton; Rhett Jiles; Carmen Ruiz Velasco; Emi Sei; Anand Kolatkar; Christopher Logothetis; Nicholas E Navin; Paul Corn; Ana M Aparicio; Ryan Dittamore; James Hicks; Peter Kuhn; Amado J Zurita
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.